

Regulatory Story

[Go to market news section](#)



Omega Diagnostics Group PLC - ODX VISITECT® CD4 commercialisation update
Released 07:00 18-Jul-2018



RNS Number : 9407U
Omega Diagnostics Group PLC
18 July 2018

Omega Diagnostics Group PLC ("Omega" or "the Company")

VISITECT® CD4 commercialisation update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its VISITECT® CD4 commercialisation programme.

The Company announces the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe. This follows on from the appointment of their first dedicated distributor for CD4 in Nigeria. All three countries require product registration, which has also commenced. Once completed, this will allow business to business sales to commence through the Company's distributors. The three countries have a high prevalence of people living with HIV and have been prioritised on that basis.

Colin King, CEO of Omega commented: *"I am pleased to see our commercialisation plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value. This also provides further evidence that our CD4 test (the world's first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments."*

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

Omega Diagnostics Group PLC
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030
www.omegadiagnostics.com

finnCap Ltd
Geoff Nash/James Thompson (Corporate

Tel: 020 7220 0500

Finance)
Camille Gochez/ Abigail Wayne (Corporate
Broking)

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
omega@walbrookpr.com
Mob: 07980 541 893
Mob: 07584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDEASXXFLFPEFF

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

VISITECT® CD4 commercialisation update - RNS